1Nelson DR, Zeldin DC, Hoffman SM, et al.Nebert DW Comparison of cytochromeP450 (CYP) genes from the mouse and human genomes, including nomenclature rec- ommendations for genes, pseudogenes and alternative- splice variants[J]. Pharmacogenetics, 2004, 14( 1 ) : 1.
3Siest G, Jeannesson E, Berrahmoune H, et al.Pharmacoge- nomics and drug response in cardiovascular disorders[J]. Pharmacogenomics, 2004,5 (7) : 779.
4Siest G, Marteau JB, Maumus S, et al.Pharmacogenomics and cardiovascular drugs: need for integrated biological systerm with phenotyoes and proiteomic markers[J]. Eur JPharmacol, 2005,527 (1-3) : 1.
6Angiolillo D J, Fema' ndez-Ortiz A, Bemardo E, et al.Con- tribution of gene sequence variations of the hepatic cyto- chrome P450 3A4 enzyme to variability in individual re- sponsiveness to clopidogrel[J]~4rterioscler Thromb Vasc Biol,2006,26(8) : 1 895.
7Lau WC, Gurbel PA, Watkins PB, et al.Contribution of he- patic cytochrome P450 3A4 metabolic activity to the phe- nomenon of clopidogrel resistance[J].Circulation, 2004, 109(2) : 166.
8Suh JW, Koo BK, Zhang SY, et al.Increased risk of ath- erothrombotic events associated with cytochrome P4503A5 polymorphism in patients taking clopidogrel[J].CMAJ, 2006,174(12):1 715.
9Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulantresponse to war- farin[J]. Pharmacogenomics, 2003,11 (3) : 202.
5Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve [J]. Transplantation, 1999 ,68( 1 ) :55 -62.
6Evans W E, McLeod H L. Pharmacogenomics-Drug disposition, drug targets and side effects [ J ]. N Engl J Med, 2003,348 ( 6 ) : 538 - 49.
7Weinshilboum R. Inheritance and drug response [ J ]. N Engl J Med, 2003,348(6) :529 -37.
8Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J]. Hum Mutat, 2004,23( 1 ) :100 -8.
9Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos [ J ]. J Pharmacol Exp Ther, 2001,299 (3) :825 -31.
10Chou F C, Tzeng S J, Huang J D. Genetic polymorphism of cytochrome P450 3A5 in Chinese [ J]. Drug Metab Dispos, 2001,29 (9) :1205 -9.
2ERCAN B,AYAZ L,GIEK D,et al.Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis[J].Cell Biochem Funct,2008,26:309-313.
3TRENK D,HOCHHOLZER W,FROMM M F,et al.Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents[J].J Am Coll Cardiol,2008,51:1925-1934.
4BIECHE I,NARJOZ C,ASSELAH T,et al.Reverse transcriptase-PCR quantfication of m RNA levels from cytochrome(CYP)1,CYP2and CYP3families in 22different human tissuses[J].Pharmacogenet Genomics,2007,17:731-742.
5KRAL B G,BECKER D M,VAIDY D,et al.Severity of inducible myocardial ischemia predicts incident acute coronary syndromes in asymptomatic individuals with a family hospital of premature coronary artery[J].J Nucl Cardiol,2012,19:28-36.
